August 12, 2021 70M Just 6 Q of cash (probably a bit more -till 1Q 23-, as they have hit pending ATM). Burn: 50M/y.
21 May 2021 Private Placement 95M $13.43
Larimar Therapeutics Announces $95 Million Private Placement Financing - Larimar Therapeutics, Inc.
On May 25, 2021 the United States Food and Drug Administration (FDA) placed a clinical hold on the CTI-1601 clinical program following the Company’s notification to the FDA of mortalities which occurred at the highest dose levels in an ongoing 180-day non-human primate (NHP) toxicology study, which is designed to support extended dosing of patients with CTI-1601.
https://twitter.com/buysidebio/status/1447651416433102850
$LRMR..$10.94..Currently on clinical hold regarding NHP tox study results; could have addt’l data package submitted to FDA by Oct, after which FDA must respond in 30 days, meaning the potential removal of clinical hold could come by EOY. -Clinical Hold lifts move hard! $PTGX 11 Oct 2021
https://twitter.com/buysidebio/status/1410637179072679940
I own this too but I am actually very concerned about the clinical hold. Precedent for monkeys’ deaths is Arrowhead years ago and they made the decision to abandon that program due to costs and burden of experiments to prove safety. Any thoughts?
HBV is dramatically different than FA. Dose margin of 15x or so for $LRMR. There’s a huge unmet need in FA with no standard of care. Given the power of FARA & the existing data in humans, I’d expect worst case a titration strategy to avoid high exposure, best case monitoring.
Still only a 250M market cap company. Will sit around 600M post any unhold. Wild how mispriced $LRMR is
$LRMR wonder where this goes if FDA asks them to dose down a la $RCKT last week. Likely still undervalued, but market pricing in reasonable uncertainty
I would assume some sort of dose titration will be proposed, which is probably a smart approach in a longer chronic dosing in patients to understand exposure. Nice to hear on call $LRMR giving more comfort RE very high dose levels drove NHP deaths
@buysidebio December 7, 2022 10:57 PM (GMT+1)
Only competitor in frataxin increase space gone $DSGN. While $LRMR completed a subset of cohort 1 out 30 days already. I'm guessing if people completed cohort1, we're not seeing accum issues over the longer 28 day study?Still a major investor focus.Surprised LRMR not up alot here
https://pbs.twimg.com/media/Fjdp2rtWAAADTNR?format=png&name=small
Funny thing is that NHP killing company $LRMR may be the last company left after $DSGN & $RETA both blow-up :) At least they show they can get FXN back to normal carrier levels. 130M mkt cap